Arzoxifene Eli Lilly

Cristina Marchisano-Karpman, Michael W. DeGregorio

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Arzoxifene is a benzothiophene second-generation selective estrogen receptor modulator (SERM) under development by Eli Lilly & Co as a potential treatment for cancer.

Original languageEnglish (US)
Pages (from-to)880-885
Number of pages6
Issue number9
StatePublished - Sep 1 2003

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Arzoxifene Eli Lilly'. Together they form a unique fingerprint.

Cite this